

#11  
DmT  
4-7-01IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Edward M. SELLERS et al.

Group Art Unit: 1651

Application Number: 09/584,669

Examiner: To Be Assigned

Filed: June 1, 2000

For: THERAPEUTIC AND DIAGNOSTIC METHODS DEPENDENT ON CYP2A ENZYMES

PRELIMINARY AMENDMENTCommissioner for Patents  
Washington, D.C. 20231

Sir:

Prior to examination of this application, please enter the following preliminary amendment.

IN THE CLAIMS:

Please amend claims 4, 7, 8, 10, 12, 15, 18, 23, 28, 30 and 31 as follows:

a<sub>1</sub> Claim 4 (amended). A method according to any one of claims 1[ to 3] or 2, further comprising administering nicotine to said individual contemporaneously with said one or more substance.

a<sub>2</sub> Claim 7 (amended). A method according to any one of claims 1 [to 6] or 2, wherein said substances which inhibit CYP2A6 are selected from methoxsalen, psoralen, tranlycypromine, pilocarpine, coumarin, chromone, esculetin, phenelzine, paroxetine, selegiline and pargyline.

Claim 8 (amended). A method according to [any one of claims 1 to 6] claim 5, wherein said substances which inhibit CYP2A6 are selected from methoxsalen, coumarin and tranlycypromine.

a<sub>3</sub> Claim 10 (amended). A method according to any one of claims [1-6] 1 or 2, wherein said substances which inhibit CYP2A6 are natural products.